GOG-0264
Terminated
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
Principal Investigator
Status
Terminated
Open to Accrual
February 8, 2010
Closed to Accrual
June 12, 2020
Closed to Accrual & Treatment
June 12, 2020
Terminated
October 11, 2024
Disease Site
Gynecologic [GY] Ovarian
Phase
II
Developmental Therapeutics
No
Primary Objective
To assess the activity of paclitaxel and carboplatin with respect to progression free survival (using bleomycin, etoposide, and cisplatin (BEP) as a reference) for newly diagnosed advanced or recurrent chemonaive ovarian sex cord-stromal tumors.
Patient Population
Paclitaxel and carboplatin with respect to progression free survival (using bleomycin, etoposide, and cisplatin (BEP) as a reference) for newly diagnosed advanced or recurrent chemonaive ovarian sex cord-stromal tumors.
Target Accrual
128
Protocol Document
Informed Consent
Tracked Amendments
Previous Protocol Versions
Previous Informed Consents
Forms
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
